Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Ann Oncol · 2011 · PMC3003617 · PMID 20643863

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The trial met its primary end point, demonstrating significantly superior PFS with the combination, and also showed a positive trend in OS in a protocol-specified interim analysis [ 9 , 10 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.